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The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been proven to be a valuable tool in allogeneic stem cell transplant (ASCT) recipients to predict overall survival. There are few studies that use the HCT-CI for evaluating autologous stem cell transplantation. Our institution performs autologous stem cell transplants in a variety of settings, from completing the whole transplant process inpatient to instituting their preparative regimen through transplant and engraftment in the outpatient setting. We retrospectively reviewed our experience of 250 autologous stem cell transplants who had a diagnosis that included Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, and Testicular Carcinoma that were either treated inpatient for their hospital course or were prepared in the outpatient setting and/or were discharged very early in their transplant course (day-1 or within three days of their autologous transplant). The median age of the inpatient transplant group was 63.5 compared to the outpatient group that was 58, P < 0.006. The average comorbidity index for the inpatient group was 2.086 compared to the outpatient group 1.23, P < 0.001. In conclusion, our institution, using the HCT-CI and age for autologous stem cell transplantation helps to identify those candidates that are more successfully treated in the inpatient setting and the outpatient setting. This study was limited by its retrospective nature, small size and single center experience. Prospective randomized studies are needed to determine whether or not the HCT-CI in autologous stem cell transplantation is truly effective. Background: There is no current standard of care for patients with newly diagnosed AL amyloidosis. Autologous HSCT is a potential option, but has been limited in its use due to increasd treatment-related mortality (TRM) (38% from one randomized study). Two large retrospective analyses showed improved overall survival (OS) (70% at 4 yrs and 47% at 5 yrs) of AL amyloid patients undergoing aHSCT compared to control (40% at 4 yrs) with TRM of 13%. Methods: We retrospectively analyzed the outcomes of 29 newly diagnosed AL amyloidosis patients who underwent aHSCT between 10/1998 and 5/2012. Hematologic responses were evaluated, along with post-transplant survival and TRM. Progression-free survival (PFS) and (OS) were determined using the Kaplan-Meier method. Results: Of the patients transplanted, 13 were female and 16 were male. Median age at aHSCT was 56 (range 26-71). Eleven (38%) had involvement of at least 2 organs. Median brain natriuretic peptide and troponin available in 20 patients were 109 pm/ml (range 24-502) and 0.02ng/ml (range 0.01-1.17). Twenty-one patients (72%) 
